Hypertension

Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation

Retrieved on: 
Tuesday, April 9, 2024
Blood pressure, Ethanol, Collateral damage, Disease, Nervous system, Patient, Renal artery, Pain, AMIX, Hypertension, Pharmaceutical industry

THE WOODLANDS, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the successful completion of an animal study evaluating the Company’s proprietary catheter-based sensing technology for use in the renal artery.

Key Points: 
  • The preclinical porcine model study was designed to assess the ability of the Company’s catheter-based sensing technology to effectively sense and target individual nerves surrounding the renal artery.
  • These results strongly demonstrate the potential of Autonomix’s sensing technology to successfully locate nerves around the renal artery.
  • These nerves include those responsible for regulating blood pressure and are the target of recently approved renal denervation procedures for hypertension.
  • The successful completion of this preclinical study provides us with confidence in the potential of our sensing technology to ultimately make renal denervation safer, faster, and more effective.

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

Retrieved on: 
Monday, April 1, 2024
Death, Adenoma, Doctor of Pharmacy, Risk, Patient, Oncology, Syndrome, Hyperglycemia, Hyperplasia, Hypertension, Pharmaceutical industry

“Hypercortisolism with adrenal etiology affects many patients and is associated with serious cardiometabolic comorbidities, including hypertension and hyperglycemia, and increased risk of premature death,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.

Key Points: 
  • “Hypercortisolism with adrenal etiology affects many patients and is associated with serious cardiometabolic comorbidities, including hypertension and hyperglycemia, and increased risk of premature death,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.
  • “GRADIENT is the first prospective placebo-controlled study to be conducted exclusively in these patients with Cushing’s syndrome.
  • We expect data from GRADIENT in the fourth quarter of this year.”
    GRADIENT is a randomized, double-blind, placebo-controlled trial conducted at sites in the United States, Europe and Israel.
  • One-hundred thirty-seven patients were randomized 1:1 to receive relacorilant or placebo for 22 weeks.

By 2035, Canada could have the most enviable healthcare system in the world if obesity is recognized as a chronic disease, predicts Obesity Canada

Retrieved on: 
Wednesday, March 27, 2024
Health, Conditional sentence, Cardiovascular disease, Conference, Obesity, Pressure, Notifiable disease, Hypertension, Diabetes, Accreditation, Research, Obesity Canada, Science, Death, Cancer, BMI, Pharmaceutical industry

The multiplication factor of obesity: Obesity is intricately linked with various chronic diseases, including cardiovascular diseases, diabetes, certain cancers, and joint problems, placing an immense burden on individual health and healthcare systems.

Key Points: 
  • The multiplication factor of obesity: Obesity is intricately linked with various chronic diseases, including cardiovascular diseases, diabetes, certain cancers, and joint problems, placing an immense burden on individual health and healthcare systems.
  • Obesity can be treated effectively; we know what to do: Canada is a global leader in obesity research and clinical expertise.
  • The Canadian Obesity Clinical Practice Guidelines are globally recognized as the gold standard and Canadian experts are highly regarded as thought leaders.
  • Revolutionizing our healthcare system: By officially recognizing obesity as a chronic disease and investing in evidence-based strategies, Canada (provincial and territorial health ministries) has the potential to lead the world in healthcare excellence within the next decade, predicts Obesity Canada.

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Retrieved on: 
Wednesday, March 27, 2024
Research, Investigational device exemption, Orchestra, HOPE, Partnership, Physician, Patient, Calibration, ISR, Medtronic, Beat (music), Insurance, Heart failure, CNT, Safety, SAB, Hypertension, PMDA, FDA, Pharmaceutical industry

Globally, the treatment of coronary in-stent restenosis and other challenging artery disease indications is rapidly shifting toward drug-coated balloons.

Key Points: 
  • Globally, the treatment of coronary in-stent restenosis and other challenging artery disease indications is rapidly shifting toward drug-coated balloons.
  • Financial Results for the Year Ended December 31, 2023
    Cash and cash equivalents and marketable securities totaled $87.6 million as of December 31, 2023.
  • Net loss for 2023 was $49.1 million, or ($1.48) per share, compared with a net loss of $33.6 million, or ($2.24) per share, for 2022.
  • Net loss for the year-ended 2023 included non-cash stock-based compensation expense of $7.6 million, compared with $3.4 million for the same period in 2022.

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Retrieved on: 
Monday, March 25, 2024
Toxicity, Nephrotoxicity, Transplant, Organ transplantation, Central nervous system, Risk, Patient, Kidney transplantation, Tacrolimus, Thumbay Hospital, Life, Kidney, Immune system, Tremor, Hypertension, Immunosuppressive drug

IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.

Key Points: 
  • IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.
  • In transplantation procedures, organ rejection is a major cause of graft failure, which can be a life-threatening condition.
  • Rejection occurs due to allorecognition, wherein the recipient's immune system identifies the transplanted organ as foreign tissue, triggering an immune response against the transplanted organ.
  • Calcineurin inhibitors (“CNIs”) are a critical component of most immunosuppressive regimens to prevent acute and long-term organ transplant rejection.

FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose

Retrieved on: 
Monday, April 8, 2024
General Health, FDA, Health, Pharmaceutical, Medical Supplies, Hypoventilation, Hypersensitivity, Nalmefene, Pulmonary edema, Caregiver, Safety, Tachycardia, Risk, New Drug Application, Patient, Ventricular tachycardia, Naloxone, Health care, Buprenorphine, Mortality, NDA, MD, Methadone, Ventricular fibrillation, Hypotension, Oxygen, LAAM, Recurrence, Allergy, Purdue University, Hypertension, Fentanyl, Pharmaceutical industry

Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.

Key Points: 
  • Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.
  • "Through this auto-injector FDA submission, our goal is to help expand the availability of nalmefene to the community alongside existing available options for healthcare professionals.
  • Priority review status means that FDA will expedite the review process to evaluate a drug that would significantly improve treatment of a serious condition.
  • Nalmefene Hydrochloride Injection is indicated in the management of known or suspected opioid overdose.

Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It

Retrieved on: 
Sunday, April 7, 2024
Health, Sports, Football, Other Health, Other Science, Research, Science, Blood pressure, TTE, FACC, African Americans, Prevalence, Aortic stenosis, National Football League, Patient, Education, Ageing, Journal, History, MD, City, Male, American College, TAVR, EKG, AFL, Interventional cardiology, Alumni association, NFL, National Football League Alumni, Hypertension, Pharmaceutical industry

Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.
  • Results of the HUDDLE study indicated that the prevalence of hypertension in the 498 screened participants was 83.8%, though only about half (46.5%) self-reported a history of hypertension.
  • Conducted across eight U.S. cities in cooperation with NFL Alumni Health, a subsidiary of the NFL Alumni Association, HUDDLE was a cross sectional study of NFL alumni and their family members aged 50 years and above.
  • Study participants self-reported their medical histories and participated in heart health education and screenings that included blood pressure, electrocardiogram (EKG) and echocardiogram.

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Retrieved on: 
Sunday, April 7, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Blood pressure, Medication, Indapamide, Risk, Patient, Month, SBP, ABPM, American College, Olmesartan, Injection, Safety, RNA interference, Therapy, AGT, ACC, Amlodipine, Cardiomyopathy, Hypertension, Pharmaceutical industry

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.

Key Points: 
  • Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
  • The results were presented today as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
  • The Company previously announced positive topline results from the KARDIA-2 study in March 2024.
  • “Although many effective oral treatments are available, a large proportion of patients with hypertension are not managed to guideline-recommended targets.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.